Exchange: NASDAQ·Updated 08:08 AM EDT
INVA logo

INVA Innoviva Inc

$21.50
$0.15
(0.70%)
Pre-Market
Prev Close $21.35
Reported EarningsAug 5
Mkt Cap$1.54B
Vol56.00

About INVA

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
50

Neutral Sentiment

How do you feel about INVA?

Advertisement|Remove ads.